Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations

Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeyakumar, Alwin, Younis, Tallal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327515/
https://www.ncbi.nlm.nih.gov/pubmed/22518088
http://dx.doi.org/10.4137/CMO.S6460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327515/
https://www.ncbi.nlm.nih.gov/pubmed/22518088
http://dx.doi.org/10.4137/CMO.S6460

Ejemplares similares